Biocon And Viatris Scoop EU Insulin Aspart Approval

Analyst Expects Biosimilar Penetration To Be ‘Slow And Minimal’

Biocon and Viatris have landed their second biosimilar insulin approval in Europe, for a rival to Novo Nordisk’s NovoRapid (insulin aspart). Analyst reaction was lukewarm considering the “disappointing” launch of insulin glargine in Europe more than two years ago.

Europe_Map_Connection
Kixelle’s approval comes soon after Biocon announced the abrupt exit of Biocon Biologics’ CEO Christiane Hamacher • Source: Shutterstock

The European Commission has rubberstamped a recommendation for approval for the Kixelle (insulin aspart) biosimilar to Novo Nordisk’s NovoRapid, handing a significant marketing authorization to the newly-formed Viatris and its development partner Biocon.

“While management has not indicated specific launch timing of the approved Kixelle, we believe it will be commercialized during the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

US Biosimilars

An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.

Amneal Kicks Off China Business With First Approval

Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

More from Generics Bulletin

GB-Business-Free-Podcast-The Secret to Walking More: It’s Not Counting Steps - Clone

 
• By 

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.